Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jörg Tomeczkowski

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 7, 2015
[Hepatitis C in Germany: an analysis of statutory sickness funds claims data]Jörg Tomeczkowski, Markus Cornberg
Clinical Pharmacology and Therapeutics|January 5, 2026
On Selection and Analytical Transparency in the FRAME Framework for RWE EvaluationJörg Tomeczkowski, Eva Susanne Dietrich
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 26, 2015
[Antiretroviral therapy for HIV/AIDS in claims data from statutory health insurance funds in Germany]Jörg Tomeczkowski, Jörg Mahlich, Matthias Stoll
Springerplus|July 9, 2015
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims dataJörg Mahlich, Johannes R Bogner, Jörg Tomeczkowski, et al.
Plos One|September 17, 2013
Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation modelJörg Tomeczkowski, Sean Stern, Alfred Müller, et al.
Pharmacoeconomics|July 27, 2025
Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology AssessmentsJörg Tomeczkowski, Tanja Heidbrede, Birte Eichinger, et al.
Advances in Therapy|September 16, 2015
Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)Jörg Tomeczkowski, Ansgar Lange, Andreas Güntert, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Deutsche Medizinische Wochenschrift (1946)|May 7, 2015
[Hepatitis C in Germany: an analysis of statutory sickness funds claims data]Jörg Tomeczkowski, Markus Cornberg
Clinical Pharmacology and Therapeutics|January 5, 2026
On Selection and Analytical Transparency in the FRAME Framework for RWE EvaluationJörg Tomeczkowski, Eva Susanne Dietrich
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 26, 2015
[Antiretroviral therapy for HIV/AIDS in claims data from statutory health insurance funds in Germany]Jörg Tomeczkowski, Jörg Mahlich, Matthias Stoll
Springerplus|July 9, 2015
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims dataJörg Mahlich, Johannes R Bogner, Jörg Tomeczkowski, et al.
Plos One|September 17, 2013
Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation modelJörg Tomeczkowski, Sean Stern, Alfred Müller, et al.
Pharmacoeconomics|July 27, 2025
Challenges and Criteria for Single-Arm Trials Leading to an Added Benefit in German Health Technology AssessmentsJörg Tomeczkowski, Tanja Heidbrede, Birte Eichinger, et al.
Advances in Therapy|September 16, 2015
Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)Jörg Tomeczkowski, Ansgar Lange, Andreas Güntert, et al.
Advances in Therapy|June 20, 2025
Letter to the Editor Regarding "Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023"Jörg Tomeczkowski, Friedhelm Leverkus, Paul Bussilliat, et al.
Clinical Pharmacology and Therapeutics|May 9, 2024
Questioning Conclusions and Statements on the German HTA System: A Critical PerspectiveJörg Tomeczkowski, Tanja Heidbrede, Friedhelm Leverkus, et al.
Pageof 1